FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W162826763> ?p ?o ?g. }

• W162826763 endingPage "137" @default.
• W162826763 startingPage "129" @default.
• W162826763 abstract "Dating to the early description of the lupus erythematosus (LE) cell in systemic lupus erythematosus (SLE), over the ensuing half century techniques for antinuclear antibody (ANA) identification have significantly evolved. Today, the term ANA is commonly used to indicate both autoantibodies to nuclear and cytoplasmic antigens, and ANA are often used as biomarkers in patients who have demonstrated autoimmune reactions against self-antigens. Some ANA, such as anti-double-stranded deoxyribonucleic acid (ds-DNA), -Sm, -topoisomerase I (Scl-70), and -Jo-1, are well known for their highly specific association with certain systemic autoimmune rheumatic diseases (SARD) and this is especially true when these specific autoantibodies are present in high titer. Studies over the past two decades have led to the general thesis that certain ANA can be detected many years prior to the diagnosis of clinical disease. Thus, some ANA can be important biomarkers for the early detection of underlying SARD; however, the fact is that most individuals with a positive ANA test do not have SARD and will not develop SARD. There are some concerns that a trend of ANA ordering by clinicians is increasing in cases with little or no clinical implication for SARD. The consequence of this putative overuse is the criticism that such practice contributes to the higher costs in healthcare spending. This issue is compounded by recent reports of inaccuracy in ANA tests conducted in many large clinical diagnostic laboratories. The cause of inaccuracy has been attributed to the introduction of screening ANA enzyme-linked immunosorbent assay (ELISA), addressable laser bead immunoassays (ALBIA), and other multiplexed immunoassays as cost-saving technologies to supposedly streamline ANA detection. The standardization of ANA assays, reporting of test results, and the appropriate utilization of this information at the clinical interface is of utmost importance if ANA testing is to continue to be a clinical useful assay for clinicians and patients alike." @default.
• W162826763 created "2016-06-24" @default.
• W162826763 creator A5009077314 @default.
• W162826763 creator A5022870216 @default.
• W162826763 creator A5053140449 @default.
• W162826763 date "2014-01-01" @default.
• W162826763 modified "2023-09-23" @default.
• W162826763 title "Antinuclear Antibodies" @default.
• W162826763 cites W160997634 @default.
• W162826763 cites W1980711342 @default.
• W162826763 cites W1985031981 @default.
• W162826763 cites W1992859365 @default.
• W162826763 cites W2022251904 @default.
• W162826763 cites W2065617048 @default.
• W162826763 cites W2078610240 @default.
• W162826763 cites W2084635564 @default.
• W162826763 cites W2109845269 @default.
• W162826763 cites W2122657747 @default.
• W162826763 cites W2159478761 @default.
• W162826763 cites W2291361009 @default.
• W162826763 doi "https://doi.org/10.1016/b978-0-444-56378-1.00015-0" @default.
• W162826763 hasPublicationYear "2014" @default.
• W162826763 type Work @default.
• W162826763 sameAs 162826763 @default.
• W162826763 citedByCount "0" @default.
• W162826763 crossrefType "book-chapter" @default.
• W162826763 hasAuthorship W162826763A5009077314 @default.
• W162826763 hasAuthorship W162826763A5022870216 @default.
• W162826763 hasAuthorship W162826763A5053140449 @default.
• W162826763 hasConcept C126322002 @default.
• W162826763 hasConcept C147483822 @default.
• W162826763 hasConcept C149443304 @default.
• W162826763 hasConcept C159654299 @default.
• W162826763 hasConcept C163764329 @default.
• W162826763 hasConcept C203014093 @default.
• W162826763 hasConcept C2776151748 @default.
• W162826763 hasConcept C2779134260 @default.
• W162826763 hasConcept C32611913 @default.
• W162826763 hasConcept C71924100 @default.
• W162826763 hasConceptScore W162826763C126322002 @default.
• W162826763 hasConceptScore W162826763C147483822 @default.
• W162826763 hasConceptScore W162826763C149443304 @default.
• W162826763 hasConceptScore W162826763C159654299 @default.
• W162826763 hasConceptScore W162826763C163764329 @default.
• W162826763 hasConceptScore W162826763C203014093 @default.
• W162826763 hasConceptScore W162826763C2776151748 @default.
• W162826763 hasConceptScore W162826763C2779134260 @default.
• W162826763 hasConceptScore W162826763C32611913 @default.
• W162826763 hasConceptScore W162826763C71924100 @default.
• W162826763 hasLocation W1628267631 @default.
• W162826763 hasOpenAccess W162826763 @default.
• W162826763 hasPrimaryLocation W1628267631 @default.
• W162826763 hasRelatedWork W149861978 @default.
• W162826763 hasRelatedWork W1967937304 @default.
• W162826763 hasRelatedWork W2003611106 @default.
• W162826763 hasRelatedWork W2017820103 @default.
• W162826763 hasRelatedWork W2076041280 @default.
• W162826763 hasRelatedWork W2252620363 @default.
• W162826763 hasRelatedWork W2318932665 @default.
• W162826763 hasRelatedWork W2332116053 @default.
• W162826763 hasRelatedWork W2369767863 @default.
• W162826763 hasRelatedWork W2409428287 @default.
• W162826763 isParatext "false" @default.
• W162826763 isRetracted "false" @default.
• W162826763 magId "162826763" @default.
• W162826763 workType "book-chapter" @default.